Uroplasty — Merger or Acquisition (December 2014)
17 slides from Uroplasty's merger presentation, Dec 22, 2014
Slide 1: Creating a Medical Device Company Positioned for Growth
December 22, 2014 Creating a Medical Device Company Positioned for Growth Draft v12 Filed by Uroplasty, Inc. pursuant to Rule to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File N
Slide 2: Forward-Looking Statements
* Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words o
Slide 3: On Today's Call
* On Today’s Call Rob KillUroplasty Chairman and CEOHoward ZaubermanVision-Sciences President and CEOBrett ReynoldsUroplasty Chief Financial Officer
Slide 4: Today's Announcement
* Today’s Announcement - COGENTIX MEDICAL -- Reserved Symbol (Nasdaq: CGNT) - - Headquarters in Minnetonka, MN -- Merger expected to accelerate growth of combined companies -- Expands innovative product offerings in Urology - - Creates platform for growth in addressable $1.3 Billion flexible endosco
Slide 5: Urology Market Dynamics
* Urology Market Dynamics Costs of practice are rising while reimbursement is relatively stablePatient population with urologic disorders is predominantly beyond middle age (> 55 years); growth in the senior population, along with the large volume of chronic conditions, is increasing patient demand
Slide 6: Company Summary: Uroplasty at a Glance
* Company Summary Proprietary Products Uroplasty at a Glance Note: 3/31 Fiscal Year End Total Revenue Founded in 1992NASDAQ: UPIHQ in Minnetonka, MNFY14 revenue: $24.6M119 team members at 9/30/14 Urgent PC Macroplastique Product Revenue Mix
Slide 7: Company Summary: Vision-Sciences at a Glance
* Company Summary Proprietary Technology Platform Vision-Sciences at a Glance Note: 3/31 Fiscal Year End Total Revenue Founded in 1987NASDAQ: VSCIHQ in Orangeburg, NYFY14 revenue: $17.1M98 team members at 9/30/14
Slide 8: Vision-Sciences EndoSheath Innovation
* Vision-Sciences EndoSheath Innovation Innovative technology ensures an “always ready, always sterile” endoscope
Slide 9: Vision-Sciences Comparative Reprocessing
* Vision-Sciences Comparative Reprocessing
Slide 10: Terms of the Merger
* Terms of the Merger All-stock transaction Uroplasty shareholders to own 62.5% and Vision-Sciences shareholders to own 37.5% upon completion of the merger (on diluted basis, excluding shares issuable upon conversion of notes and warrants held by Vision-Sciences’ Board Chairman, which were amended i
Slide 11: Cogentix Medical Financial Profile
* Cogentix Medical Financial Profile $41.7 million in fiscal year 2014$24.6 million for Uroplasty$17.1 million for Vision-SciencesAccelerating future revenue growth TTM revenue growth of 10.9%11% to 14% revenue growth anticipated for fiscal year beginning April 1, 201515% sustainable revenue growth
Slide 12: Depth & Breadth of Leadership Team and Distribution Platform
* Depth & Breadth of Leadership TeamDistribution Platform44 U.S. Sales Reps – Uroplasty12 U.S. Sales Reps - Vision Sciences8 International Sales RepsDistributor RelationshipsFunctional ExpertiseSalesMarketingRegulatoryQuality Reimbursement Cogentix Medical Growth Strategy Licensing & acquisition opp
Slide 13: Cogentix Medical Growth Strategy
* Cogentix Medical Growth Strategy GoalsAcquire innovative assets at attractive valuations Accelerate revenue growth to 15% for products in portfolio Reward shareholders through improved valuationMetricsAnticipated near-term revenue of ~ $50 millionAspire to $100 million of revenue within three year
Slide 14: Summary: Expected Benefits to Shareholders
* Summary Expected Benefits to ShareholdersCreates Medical Device company positioned for growthGreater scale and stronger financial profileAccelerated revenue growth anticipated by leveraging existing capacity of Uroplasty sales teamExpands product offerings in UrologyExtends platform for growth in
Slide 15: Your Questions
Your Questions Cogentix 4\ Medical Uroplasty >< + VISION ‘ ' . Uroplasty?~ 1s VISION sciences:
Slide 16: Contact information
EVC GROUPDOUG SHERKDSHERK@EVCGROUP.COM415.652.9100BRIAN MOOREBMOORE@EVCGROUP.COM310.579.6199JANINE MCCARGO (MEDIA)JMCCARGO@EVCGROUP.COM646.688.0425 For additional information, please contact: UROPLASTY & VISION-SCIENCESBRETT REYNOLDSCFO, UROPLASTY BRETT.REYNOLDS@UROPLASTY.COM952.426.6152GARY SIEGELV
Slide 17: Important Additional Information About This Transaction and Where to Find It
* Important Additional Information About This Transaction and Where to Find ItIn connection with the proposed merger, Vision-Sciences plans to file with the SEC a registration statement on Form S-4 that will include a joint proxy statement of Uroplasty and Vision-Sciences that also constitutes a pro